1. Home
  2. PRAX vs GSAT Comparison

PRAX vs GSAT Comparison

Compare PRAX & GSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$345.30

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Globalstar Inc.

GSAT

Globalstar Inc.

HOLD

Current Price

$81.59

Market Cap

10.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
GSAT
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.7B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
PRAX
GSAT
Price
$345.30
$81.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
2
Target Price
$572.13
$70.50
AVG Volume (30 Days)
311.4K
631.1K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.58
EPS
N/A
N/A
Revenue
N/A
$112,660,000.00
Revenue This Year
N/A
$10.31
Revenue Next Year
$7,758.26
$15.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$29.36
52 Week High
$392.70
$84.85

Technical Indicators

Market Signals
Indicator
PRAX
GSAT
Relative Strength Index (RSI) 47.08 50.21
Support Level $285.26 $81.84
Resistance Level $356.02 $82.10
Average True Range (ATR) 17.13 0.62
MACD -4.00 -0.07
Stochastic Oscillator 21.92 55.45

Price Performance

Historical Comparison
PRAX
GSAT

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About GSAT Globalstar Inc.

Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services, including voice and data communications services to retail, business, and governmental customers, as well as wholesale satellite capacity services. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is the owner of satellite assets. It has one reportable segment: the MSS business. The company generates the vast majority of its revenue within the United States.

Share on Social Networks: